• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Fennec Pharmaceuticals Inc.

    12/2/24 4:06:55 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FENC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001185945
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    FENNEC PHARMACEUTICALS INC.
    SEC File Number
    001-32295
    Address of Issuer
    PO BOX 13628, 68 TW ALEXANDER DRIVE
    Research Triangle Park
    NORTH CAROLINA
    27709
    Phone
    (919) 636-4530
    Name of Person for Whose Account the Securities are To Be Sold
    CHRIS A RALLIS
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    640939344.212743223412/02/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/02/2024Stock Option ExerciseISSUERCheckbox not checked640912/02/2024Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    CHRIS A RALLIS
    PO BOX 13628, 68 TW ALEXANDER DRIVE
    Research Triangle Park � NC � 27709
    Common10/08/202414066369.18

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/02/2024
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/17/2023

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Chris Anigeron Rallis

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $FENC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FENC

    DatePrice TargetRatingAnalyst
    2/12/2026$16.00Buy
    B. Riley Securities
    1/9/2026Overweight
    Piper Sandler
    11/22/2022$9.00 → $12.00Neutral → Overweight
    Cantor Fitzgerald
    9/7/2022$11.00Overweight
    CapitalOne
    8/8/2022$14.00Buy
    Craig Hallum
    More analyst ratings

    $FENC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Fennec Pharmaceuticals with a new price target

    B. Riley Securities initiated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $16.00

    2/12/26 7:24:33 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Fennec Pharmaceuticals

    Piper Sandler initiated coverage of Fennec Pharmaceuticals with a rating of Overweight

    1/9/26 9:04:54 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

    11/22/22 9:21:25 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hackman Jeffrey S. bought $104,602 worth of shares (15,000 units at $6.97) (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    5/19/25 5:42:21 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Andrade Robert bought 12,500 shares, increasing direct ownership by 14% to 104,271 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    4/3/24 5:00:11 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raykov Rosty bought 29,167 shares, increasing direct ownership by 10% to 316,638 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    4/3/24 4:55:10 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PEDMARK issued to FENNEC PHARMACEUTICALS INC

    Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/20/22 3:54:04 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Raykov Rosty exercised 15,598 shares at a strike of $2.45 and sold $80,308 worth of shares (10,349 units at $7.76), increasing direct ownership by 6% to 98,477 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    2/2/26 4:54:52 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Raykov Rosty was granted 5,208 shares, increasing direct ownership by 6% to 93,228 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    2/2/26 4:05:20 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,558 shares, increasing direct ownership by 0.74% to 212,658 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    2/2/26 4:05:19 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

    NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP ("Southpoint"), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a "Common Share") of Fennec Pharmaceuticals Inc. ("Fennec"), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis). The Common Shares were sold at a price of USD$7.50 per Common Share. Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Commo

    12/26/25 5:44:05 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

    – City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of Hearing Loss Among Patients Receiving Cisplatin-Based Chemotherapy – RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced the planned initiation of an investigator-sponsored study (IST) by City of Hope, a U.S. cancer research and treatment organization, to evaluate PEDMARK® (sodium thiosulfate injection) for the prevention of cisplatin-induced ototoxicity (CIO

    12/9/25 7:00:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

    – Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) – – PEDMARK® Showed No Interference with Cisplatin Antitumor Activity as Evidenced by an Approximate 95% Clinical Response Rate – – The Company Plans to Pursue Registration and is Exploring Partnering or Licensing Opportunities for PEDMARK® in Japan Based Upon These Results – RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty p

    12/2/25 7:01:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    SEC Filings

    View All

    Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    12/9/25 4:02:02 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    12/2/25 4:02:26 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    11/19/25 7:10:41 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Leadership Updates

    Live Leadership Updates

    View All

    Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

    ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c

    8/5/24 6:26:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Financials

    Live finance-specific insights

    View All

    Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

    ~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient Support Services for PEDMARK® ~ ~ Successful Initial Uptake of PEDMARQSI® in the United Kingdom and Germany with Additional EU Launches Planned ~ ~ Japan Clinical Trial (STS-J01) Results Expected in the Second Half of 2025 with Evaluation of Both Registration and Partnering or Licensing Expected Thereafter ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.

    8/14/25 6:08:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

    RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Thursday, August 14, 2025Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/de4jxxzj   Participant Link: https://register-conf.media-server.com/register/BI3e750b95d06c439ea560b

    8/11/25 7:12:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro

    5/13/25 6:03:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fennec Pharmaceuticals Inc.

    SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    11/12/24 7:38:18 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

    SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    6/27/24 4:43:33 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

    SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    2/14/24 10:47:17 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care